Peer Review History

Original SubmissionMarch 2, 2025
Decision Letter - Shengqian Sun, Editor

PONE-D-25-10015Identification of immune-related biomarkers associated with allergic rhinitis and development of a sample diagnostic modelPLOS ONE

Dear Dr. Zhang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 03 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Shengqian Sun

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that PLOS ONE has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.

3. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

4. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

5. Thank you for stating the following financial disclosure:

“This work was supported by Shandong Province Natural Science Foundation youth project (grant number ZR2023QH460) and the Key research and development program of Shandong (grant number 2022CXPT023).”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

6. We note that your Data Availability Statement is currently as follows: “All relevant data are within the manuscript and in Supporting Information files.”

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

7. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript presents a comprehensive bioinformatics and experimental approach to identify immune-related biomarkers for allergic rhinitis (AR) and to develop a gene-based diagnostic model. The authors successfully integrate transcriptomic data, network analysis, machine learning, and animal model validation. The study is well-structured, methodologically sound, and contributes valuable insights into AR diagnostics and potential therapeutic targets. In my opinion, the manuscript present a well-executed study offering a novel and clinically relevant diagnostic model for AR based on immune-related biomarkers. This manuscript is suitable for publication in is current form.

Reviewer #2: Line 33 and 36. sva and limma need full names or nomenclature. What software have been used for the package? Please be specific in the abstract.

Line 39. SVM and ROC are famous but still need full name at the first time showing up.

Line 23. Although it is the trend fashion using 'We' and it seems for emphasizing the major 'achievement' of a study in generally abstract and conclusion sections, please apply passive transformation for most part of scientific manuscript.

Line 169. Any ethical review protocol has been applied for the mice experiment?

Line 229. 'Error! Reference source not found.' seems something wrong.

Line 254. The author should provide more infomation about Figure 5 volcano plot, what information can be extracted from the volcano plot?

Line 367. substantiates may be too strong for science, probably using indicates or suggests would be better.

Line 380. 'In line with our study,' please indicate which figures or tables are 'in line with' and how?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: Yes:  Dr Daniel Elbirt

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

Dear Editor and Reviewers,

We sincerely appreciate the time and effort you have dedicated to reviewing our manuscript entitled “Identification of immune-related biomarkers associated with allergic rhinitis and development of a sample diagnostic model” (ID: PONE-D-25-10015). Your insightful comments and constructive suggestions have been invaluable in improving the quality and clarity of our work. We have carefully addressed the points raised, and the revisions are highlighted in yellow in the revised manuscript. Below, we provide a detailed response to each reviewer's comments.

Responses to reviews (original comments by reviews are in blue color)

Reviewer # 1:

Comment: This manuscript presents a comprehensive bioinformatics and experimental approach to identify immune-related biomarkers for allergic rhinitis (AR) and to develop a gene-based diagnostic model. The authors successfully integrate transcriptomic data, network analysis, machine learning, and animal model validation. The study is well-structured, methodologically sound, and contributes valuable insights into AR diagnostics and potential therapeutic targets. In my opinion, the manuscript present a well-executed study offering a novel and clinically relevant diagnostic model for AR based on immune-related biomarkers. This manuscript is suitable for publication in is current form.

Reply: We sincerely express our gratitude for your acknowledgment and endorsement of our work.

Reviewer # 2:

1. Comment: Line 33 and 36. sva and limma need full names or nomenclature. What software have been used for the package? Please be specific in the abstract.

Reply: We sincerely appreciate your thoughtful review and valuable feedback on our manuscript. In response we have now consistently supplemented the full nomenclature of the bioinformatics tools “sva” (Surrogate Variable Analysis) and “limma” (Linear Models for Microarray Data) in the abstract. Regarding software implementation, we have explicitly specified the utilization of R packages along with their corresponding versions to ensure complete consistency between the Abstract and Methods sections. (The requested revisions have been implemented in Lines 40-46 of the file labeled 'Revised Manuscript with Track Changes', with all modifications highlighted in yellow for clarity).

2. Comment: Line 39. SVM and ROC are famous but still need full name at the first time showing up.

Reply: Thank you very much for your constructive suggestions. In response, we have thoroughly addressed the requested revisions as follows: In Lines 49-51 of the file labeled 'Revised Manuscript with Track Changes' (highlighted in yellow), we introduced the full terms "Support Vector Machine (SVM)" and "Receiver Operating Characteristic (ROC)" upon their first appearance. To ensure terminological consistency, we have systematically standardized all technical acronyms throughout the manuscript following the "Full Name (Acronym)" format upon initial use, thereby maintaining uniform compliance across all sections.

3. Comment: Line 23. Although it is the trend fashion using 'We' and it seems for emphasizing the major 'achievement' of a study in generally abstract and conclusion sections, please apply passive transformation for most part of scientific manuscript.

Reply: We sincerely thank the reviewer for their valuable guidance on scientific writing conventions. In accordance with this recommendation, we have systematically transformed active constructions into passive voice throughout the manuscript, paying particular attention to the Abstract and Conclusion sections. These revisions ensure complete adherence to the journal's prescribed style for objective academic discourse while maintaining methodological precision.

4. Comment: Line 169. Any ethical review protocol has been applied for the mice experiment?

Reply: Thanks very much for your valuable questions. We confirm full adherence to international standards for the animal research ethics. The study was conducted under ethical approval No, 2025-083 granted by the Animal Experiment Ethics Committee of Yuhuangding Hospital, with all procedures strictly performed in accordance with the approved guidelines. We have provided additional details regarding the animal experiments, including methods of euthanasia and anesthesia, as well as measures implemented to minimize suffering. (The requested revisions have been implemented in Lines 171-173 and Lines 185-190 of the file labeled 'Revised Manuscript with Track Changes', with all modifications highlighted in yellow for clarity).

5. Comment: Line 229. 'Error! Reference source not found.' seems something wrong.

Reply: We sincerely appreciate your suggestion and apologize for the oversight. We confirm that this issue stemmed from a technical artifact caused by figure-format incompatibility during the initial submission process. The revised manuscript now accurately displays all references, as evidenced at Line 236 of the file labeled 'Revised Manuscript with Track Changes' (highlighted in yellow) and consistently throughout the document, with all formatting errors fully resolved.

6. Comment: Line 254. The author should provide more information about Figure 5 volcano plot, what information can be extracted from the volcano plot?

Reply: We sincerely appreciate your detailed comments and suggestions. In Lines 258-264 of the file labeled 'Revised Manuscript with Track Changes' (with all modifications highlighted in yellow), we have supplemented essential information regarding the interpretation of the volcano plot.

7. Comment: Line 367. substantiates may be too strong for science, probably using indicates or suggests would be better.

Reply: We sincerely appreciate this insightful linguistic correction. In Line 363 of the file labeled 'Revised Manuscript with Track Changes' (highlighted in yellow), the verb "substantiates" has been replaced with "suggests" to more precisely convey the inferential nature of our findings.

8. Comment: Line 380. 'In line with our study,' please indicate which figures or tables are 'in line with' and how?

Reply: We sincerely thank you for your constructive suggestion. In Lines 374-378 of the file labeled 'Revised Manuscript with Track Changes' (with all modifications highlighted in yellow), we have revised the text to explicitly establish a connection between our data and the Th2-immunity mechanism, while providing figure-based evidence to support this linkage.

Once again, we extend our sincere gratitude to the reviewers and editors for their invaluable contributions. We believe that the manuscript has been significantly enhanced, and we look forward to its potential publication in your esteemed journal.

Sincerely,

Hua Zhang

Attachments
Attachment
Submitted filename: Responses to Reviewers.docx
Decision Letter - Shengqian Sun, Editor

Identification of immune-related biomarkers associated with allergic rhinitis and development of a sample diagnostic model

PONE-D-25-10015R1

Dear Dr. Zhang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Shengqian Sun

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Regarding your email query about the clarification of Dr. XueXia Liu’s affiliation, this minor correction should be addressed during the production stage in accordance with PLoS ONE policy. Please notify the production team once your manuscript reaches that phase.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The authors have significantly improved the manuscript, and all key issues have been addressed, so I have no further questions.

Cheers,

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Shengqian Sun, Editor

PONE-D-25-10015R1

PLOS ONE

Dear Dr. Zhang,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Shengqian Sun

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .